Wednesday, September 2, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 23, 2026

AstraZeneca Deepens China Roots With Shanghai Cell Therapy Manufacturing Push

View original at finance.yahoo.com
AstraZeneca Deepens China Roots With Shanghai Cell Therapy Manufacturing Push Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The company is committed to invest US$15 billion in China's biotech sector through 2030

    60% confidence

  • AstraZeneca is the first multinational with end-to-end cell therapy manufacturing capability in China

    60% confidence

Data points we hold from this source

AstraZeneca AB · return 1year21.8 percent
AstraZeneca AB · return 1month-9.0 percent
AstraZeneca AB · return 1week-3.4 percent
AstraZeneca AB · return 3year33.2 percent
AstraZeneca AB · return 5year112.4 percent
AstraZeneca AB · return ytd2.2 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge: Late-August 2026 Funding Wave Spans Fintech, Enterprise Agents, and Robotics
A dense cluster of funding rounds landing on 2026-08-28 — from identity/fraud fintech player Socure ($156M plus its acquisition of Fravity) to enterprise AI agent startups (Instinct, Generalist AI, Owner), model infrastructure (Stability AI, Emerald AI), and autonomous logistics/aerospace (Gatik, Regent Craft) — signals investors are rotating aggressively into AI-native companies with demonstrable ROI, especially in financial risk/compliance and back-office automation. Parallel signals (Multiverse Computing's compression benchmarks cutting inference cost/latency, and Arkestro/CloneOps.ai publishing hard savings and labor-displacement figures) suggest the funding is chasing efficiency and measurable economic impact rather than pure model scale.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,980
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,980 facts checked against source5,267 source documents archived
Query this data → isubstrate.com